MedTrace Logo

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

NCT04047680 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 441

Last updated 2019-08-08

No results posted yet for this study

Summary

Data regarding the nephrotoxicity of sofosbuvir (SOF) remain controversial. The investigators compared the changes of estimated glomerular filtration rate (eGFR) in patients with chronic hepatitis C virus (HCV) infection receiving SOF-based or SOF-free direct acting antivirals (DAAs).

Conditions

  • Hepatitis C
  • Renal Disease
  • Viral Hepatitis C

Interventions

DRUG

Sofosbuvir / Velpatasvir Oral Tablet

Sofosbuvir/velpatasvir for 12 weeks

DRUG

Sofosbuvir and Ledipasvir

Sofosbuvir and ledipasvir for 12 weeks

DRUG

Sofosbuvir Tablets

Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks

DRUG

Ombitasvir/paritaprevir/ritonavir

Ombitasvir/paritaprevir/ritonavir for 12 weeks

DRUG

Elbasvir / Grazoprevir Oral Tablet

Elbasvir/grazoprevir for 12 weeks

DRUG

Glecaprevir and Pibrentasvir

Glecaprevir/pibrentasvir for 12 weeks

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Jia-Horng Kao, PhD · National Taiwan University Hospital

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2018-12-31
Completion
2019-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04047680 on ClinicalTrials.gov